Topics:
Thoracic Malignancies • Medical Oncology
Would you avoid cisplatin with etoposide in a patient getting chemoradiotherapy for stage III non-squamous NSCLC who has a history of CABG 4 years ago and echocardiogram showing left atrial dilatation?
Answer from: Medical Oncologist at Community Practice
In short, I would avoid cisplatin here. The main issue with cisplatin is the need for fairly aggressive hydration to avoid nephrotoxicity. Generally, at least 1-2 L IV NS hydration is given, however, some will give up to 3L, in addition to the volume infused with actual treatment (usually diluted in...
Sign in or Register to read more